The prevalence of defects in DNA repair genes, particularly alterations in HRR genes, ranges from 19 to 33% among individuals with prostate cancer, depending on whether primary or metastatic tumor tissue is considered [9–11] BRCA2 alterations emerge as the most prevalent in metastatic disease [9–13]. Here, BRCA2 is linked to prostate cancer.